Lantern Pharma Engages IBN for Corporate Communications Strategy Amid AI-Driven Oncology Pipeline Advancements

Lantern Pharma (NASDAQ: LTRN), a biotechnology firm utilizing its RADR(R) AI platform for precision oncology drug development, has announced a partnership with IBN to spearhead its corporate communications strategy. This collaboration comes as Lantern Pharma advances its clinical programs targeting various cancers, including lung, brain, breast, and blood cancers, with three AI-guided candidates and a subsidiary focused on central nervous system (CNS) therapies. The company is currently conducting active trials for multiple FDA-designated therapies, aiming to leverage this partnership to increase investor awareness and support the achievement of critical milestones in its data-driven, biomarker-informed pipeline. For more details, visit https://ibn.fm/6gYcX.